Insider Transactions Reported by 15 Insiders of Evommune, Inc.

Symbol: EVMN on NYSE
Location: Palo Alto, CA

Quick Takeaways

EVMN - Evommune, Inc. has 15 insiders with reported activity on this page.
Net insider value flow over the last year: +$17,350.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $17,350; sell value: $0.
Net share flow: <span class="text-green-600">+1,000</span>.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$17,350.

Buys

$17,350

Shares: 1,000

Insiders: 1

Sells

Shares: 0

Insiders: 0

Net

+$17,350

Shares: +1,000

Insiders: 1

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	1,000	$17,350	$0	+$17,350
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

Evommune, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Isabel Verduyn van Weegen	Director, 10%+ Owner	$147,438,166			Mixed	17 Feb 2026
7. Cooperative Ua Lsp	Director, 10%+ Owner	$147,438,166			Mixed	17 Feb 2026
RA CAPITAL MANAGEMENT, L.P.	Director	$75,562,968			Mixed	17 Feb 2026
Robert Lorne Hopfner	Director, 10%+ Owner	$63,219,381	+$17,350	+0.03%	Mixed	19 Dec 2025
Luis C. Pena	President & CEO, Director	$11,679,544			Mixed	09 Dec 2025
Eugene Bauer	Chief Medical Officer, Director	$4,831,393			Mixed	09 Dec 2025
Janice Suzann Drew	EVP, Operations	$1,209,444			Mixed	09 Dec 2025
Gregory S. Moss	Chief Business & Legal Officer	$1,147,113			Mixed	09 Dec 2025
Kyle Carver	Chief Financial Officer	$1,115,178			Mixed	09 Dec 2025
Jeegar Pravinkumar Patel	Chief Scientific Officer	$884,471			Mixed	09 Dec 2025
Benjamin F. Mcgraw III	Director				Mixed	05 Nov 2025
Derek DiRocco	Director				Mixed	05 Nov 2025
David E. Cohen	Director				Mixed	07 Nov 2025
Pivotal bioVenture Partners Fund I, L.P.	Director, 10%+ Owner				Mixed	07 Nov 2025
Arthur S. Kirsch	Director				Mixed	05 Nov 2025

Top shareholders of Evommune, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
7. Cooperative Ua Lsp	3/4/5 13D/G	Director, 10%+ Owner · LSP 7 Cooperatieve U.A.	15% from 13D/G	5,288,313	$147,438,166	—	17 Feb 2026	3/4/5 13D/G
Isabel Verduyn van Weegen	3/4/5	Director, 10%+ Owner	15%	5,288,313	$147,438,166	—	17 Feb 2026	3/4/5
EQT Fund Management S.a r.l.	13F	Company	14%	4,929,633	$84,395,317	—	31 Dec 2025	13F
RA CAPITAL MANAGEMENT, L.P.	3/4/5 13D/G 13F	Director · Company	9.7% from 13D/G	2,710,293	$75,562,968	—	17 Feb 2026	3/4/5 13D/G 13F
Pivotal bioVenture Partners Fund I, L.P.	13D/G 3/4/5	Nan Fung Group Holdings Limited · Director, 10%+ Owner	11%	3,435,599	$69,158,608	$0	31 Dec 2025	13D/G 3/4/5
Robert Lorne Hopfner	3/4/5	Director, 10%+ Owner	9.4%	3,372,001	$63,219,381	+$17,350	19 Dec 2025	3/4/5
Pivotal bioVenture Partners Investment Advisor LLC	13F	Company	5.4%	1,926,943	$32,989,264	—	31 Dec 2025	13F
Andera Partners	13F 13D/G	Company	6% from 13D/G	1,897,362	$32,482,837	—	31 Dec 2025	13F 13D/G
Nan Fung Group Holdings Ltd	13F	Company	4%	1,441,032	$24,670,468	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	3.6%	1,308,901	$22,408,385	—	31 Dec 2025	13F
RTW INVESTMENTS, LP	13F	Company	3.6%	1,283,671	$21,976,448	—	31 Dec 2025	13F
SymBiosis Capital Partners, LLC	13F	Company	3.6%	1,280,778	$21,926,919	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	2.7%	988,200	$16,917,986	—	31 Dec 2025	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	2.7%	961,525	$16,461,308	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	2.2%	782,121	$13,391,000	—	31 Dec 2025	13F
Luis C. Pena	3/4/5	President & CEO, Director	— mixed-class rows	1,451,524 mixed-class rows	$11,679,544	—	09 Dec 2025	3/4/5
SECTORAL ASSET MANAGEMENT INC	13F	Company	1.6%	589,005	$10,083,766	—	31 Dec 2025	13F
Verition Fund Management LLC	13F	Company	1.6%	565,214	$9,676,464	—	31 Dec 2025	13F
Aberdeen Group plc	13F	Company	1.5%	525,376	$8,994,437	—	31 Dec 2025	13F
Velan Capital Investment Management LP	13F	Company	1.4%	506,754	$8,675,628	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	1.4%	502,574	$8,604,067	—	31 Dec 2025	13F
Octagon Capital Advisors LP	13F	Company	1.4%	500,000	$8,560,000	—	31 Dec 2025	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	1.2%	417,455	$7,146,850	—	31 Dec 2025	13F
FEDERATED HERMES, INC.	13F	Company	0.9%	325,000	$5,564,000	—	31 Dec 2025	13F
GREAT POINT PARTNERS LLC	13F	Company	0.9%	325,000	$5,564,000	—	31 Dec 2025	13F
Eugene Bauer	3/4/5	Chief Medical Officer, Director	— mixed-class rows	370,818 mixed-class rows	$4,831,393	—	09 Dec 2025	3/4/5
NEXTBio Capital Management LP	13F	Company	0.63%	228,286	$3,908,256	—	31 Dec 2025	13F
Defilade Capital Management, L.P.	13F	Company	0.6%	215,418	$3,687,956	—	31 Dec 2025	13F
Kynam Capital Management, LP	13F	Company	0.52%	185,482	$3,175,452	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.51%	184,062	$3,151,141	—	31 Dec 2025	13F
Monashee Investment Management LLC	13F	Company	0.51%	183,239	$3,137,052	—	31 Dec 2025	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.46%	166,147	$2,844,437	—	31 Dec 2025	13F
Sofinnova Investments, Inc.	13F	Company	0.43%	153,320	$2,624,838	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.4%	142,440	$2,438,573	—	31 Dec 2025	13F
Integral Health Asset Management, LLC	13F	Company	0.35%	125,000	$2,140,000	—	31 Dec 2025	13F
MPM BioImpact LLC	13F	Company	0.31%	113,022	$1,934,937	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.31%	109,781	$1,880,534	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.29%	104,555	$1,789,982	—	31 Dec 2025	13F
SEVEN GRAND MANAGERS, LLC	13F	Company	0.21%	75,000	$1,284,000	—	31 Dec 2025	13F
Janice Suzann Drew	3/4/5	EVP, Operations	— mixed-class rows	299,068 mixed-class rows	$1,209,444	—	09 Dec 2025	3/4/5
STEMPOINT CAPITAL LP	13F	Company	0.19%	68,196	$1,167,516	—	31 Dec 2025	13F
Gregory S. Moss	3/4/5	Chief Business & Legal Officer	— mixed-class rows	357,506 mixed-class rows	$1,147,113	—	09 Dec 2025	3/4/5
Kyle Carver	3/4/5	Chief Financial Officer	— mixed-class rows	341,918 mixed-class rows	$1,115,178	—	09 Dec 2025	3/4/5
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.18%	65,000	$1,112,800	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.17%	62,704	$1,073,492	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.17%	61,675	$1,055,876	—	31 Dec 2025	13F
Capricorn Fund Managers Ltd	13F	Company	0.17%	60,000	$1,027,200	—	31 Dec 2025	13F
Jeegar Pravinkumar Patel	3/4/5	Chief Scientific Officer	— mixed-class rows	229,197 mixed-class rows	$884,471	—	09 Dec 2025	3/4/5
CITADEL ADVISORS LLC	13F	Company	0.14%	50,560	$865,587	—	31 Dec 2025	13F
Burkehill Global Management, LP	13F	Company	0.14%	50,000	$856,000	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Evommune, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
7. Cooperative Ua Lsp	EVMN	Common Stock	Award	7.28%			358,680	5,288,313	17 Feb 2026	See footnote
Isabel Verduyn van Weegen	EVMN	Common Stock	Award	7.28%			358,680	5,288,313	17 Feb 2026	By LSP 7 Cooperatief U.A.
Ra Capital Management, L.P.	EVMN	Common Stock	Award	1.34%			35,868	2,710,293	17 Feb 2026	See Footnotes
Robert Lorne Hopfner		Common Stock	Purchase	33%	$17,350	$17.35	1,000	4,026	19 Dec 2025	By Trust
Luis C. Pena		Common Stock	Tax liability	-4.12%			-28,138	654,683	09 Dec 2025	Direct
Jeegar Pravinkumar Patel		Common Stock	Tax liability	-13.2%			-7,513	49,578	09 Dec 2025	Direct
Gregory S. Moss		Common Stock	Tax liability	-18.3%			-13,624	60,835	09 Dec 2025	Direct
Janice Suzann Drew		Common Stock	Tax liability	-6.96%			-5,074	67,794	09 Dec 2025	Direct
Kyle Carver		Common Stock	Tax liability	-17.5%			-13,290	62,510	09 Dec 2025	Direct
Eugene Bauer		Common Stock	Tax liability	-0.54%			-1,478	270,818	09 Dec 2025	Direct
Eugene Bauer		Employee Stock Option (Right to Buy)	Award				100,000	100,000	08 Dec 2025	Direct
Isabel Verduyn van Weegen		Common Stock	Purchase	46.4%			1,562,500	4,929,633	07 Nov 2025	By LSP 7 Cooperatief U.A.
Isabel Verduyn van Weegen		Common Stock	Conversion of derivative security				3,367,133	3,367,133	07 Nov 2025	By LSP 7 Cooperatief U.A.
Isabel Verduyn van Weegen		Series C Preferred Stock	Conversion of derivative security	-100%			-6,585,011	0	07 Nov 2025	By LSP 7 Cooperatief U.A.
Isabel Verduyn van Weegen		Series B Preferred Stock	Conversion of derivative security	-100%			-5,090,000	0	07 Nov 2025	By LSP 7 Cooperatief U.A.
Isabel Verduyn van Weegen		Series A Preferred Stock	Conversion of derivative security	-100%			-15,493,466	0	07 Nov 2025	By LSP 7 Cooperatief U.A.
Jeegar Pravinkumar Patel		Common Stock	Conversion of derivative security	5.89%			3,175	57,091	07 Nov 2025	Direct
Jeegar Pravinkumar Patel		Series B Preferred Stock	Conversion of derivative security	-100%			-25,000	0	07 Nov 2025	Direct
Janice Suzann Drew		Common Stock	Conversion of derivative security	2.23%			1,587	72,868	07 Nov 2025	Direct
Janice Suzann Drew		Series B Preferred Stock	Conversion of derivative security	-100%			-12,500	0	07 Nov 2025	Direct
7. Cooperative Ua Lsp		Common Stock	Purchase	46.4%			1,562,500	4,929,633	07 Nov 2025	Direct
7. Cooperative Ua Lsp		Common Stock	Conversion of derivative security				3,367,133	3,367,133	07 Nov 2025	Direct
7. Cooperative Ua Lsp		Series C Preferred Stock	Conversion of derivative security	-100%			-6,585,011	0	07 Nov 2025	Direct
7. Cooperative Ua Lsp		Series B Preferred Stock	Conversion of derivative security	-100%			-5,090,000	0	07 Nov 2025	Direct
7. Cooperative Ua Lsp		Series A Preferred Stock	Conversion of derivative security	-100%			-15,493,466	0	07 Nov 2025	Direct
Kyle Carver		Common Stock	Conversion of derivative security	4.37%			3,175	75,800	07 Nov 2025	Direct
Kyle Carver		Series B Preferred Stock	Conversion of derivative security	-100%			-25,000	0	07 Nov 2025	Direct
Gregory S. Moss		Common Stock	Conversion of derivative security				3,175	3,175	07 Nov 2025	By Trust
Gregory S. Moss		Series B Preferred Stock	Conversion of derivative security	-100%			-25,000	0	07 Nov 2025	By Trust
Pivotal bioVenture Partners Fund I, L.P.		Common Stock	Conversion of derivative security				3,367,975	1,632,441	07 Nov 2025	See footnotes
Pivotal bioVenture Partners Fund I, L.P.		Series C Preferred Stock	Conversion of derivative security	-100%			-3,135,717	0	07 Nov 2025	See footnotes
Pivotal bioVenture Partners Fund I, L.P.		Series B Preferred Stock	Conversion of derivative security	-100%			-4,000,000	0	07 Nov 2025	See footnotes
Pivotal bioVenture Partners Fund I, L.P.		Series A Preferred Stock	Conversion of derivative security	-100%			-9,812,526	0	07 Nov 2025	See footnotes
Pivotal bioVenture Partners Fund I, L.P.		Series Seed Preferred Stock	Conversion of derivative security	-100%			-10,718,463	0	07 Nov 2025	See footnotes
Eugene Bauer		Common Stock	Conversion of derivative security	10.5%			25,812	272,296	07 Nov 2025	Direct
Eugene Bauer		Series B Preferred Stock	Conversion of derivative security	-100%			-12,500	0	07 Nov 2025	Direct
Eugene Bauer		Series Seed Preferred Stock	Conversion of derivative security	-100%			-206,355	0	07 Nov 2025	Direct
Luis C. Pena		Common Stock	Conversion of derivative security	3.68%			24,225	682,821	07 Nov 2025	Direct
Luis C. Pena		Series Seed Preferred Stock	Conversion of derivative security	-100%			-206,355	0	07 Nov 2025	Direct
Robert Lorne Hopfner		Common Stock	Conversion of derivative security				294,502	294,502	07 Nov 2025	By Pivotal bioVenture Partners Fund II, L.P.
Robert Lorne Hopfner		Common Stock	Conversion of derivative security				1,632,441	1,632,441	07 Nov 2025	By Pivotal bioVenture Partners Fund I, L.P.
Robert Lorne Hopfner		Common Stock	Conversion of derivative security				1,441,032	1,441,032	07 Nov 2025	By NFLS Delta III Limited
Robert Lorne Hopfner		Common Stock	Conversion of derivative security				3,026	3,026	07 Nov 2025	By Trust
Robert Lorne Hopfner		Series C Preferred Stock	Conversion of derivative security	-100%			-2,508,575	0	07 Nov 2025	By Pivotal bioVenture Partners Fund II, L.P.
Robert Lorne Hopfner		Series C Preferred Stock	Conversion of derivative security	-100%			-313,571	0	07 Nov 2025	By Pivotal bioVenture Partners Fund I, L.P.
Robert Lorne Hopfner		Series C Preferred Stock	Conversion of derivative security	-100%			-313,571	0	07 Nov 2025	By NFLS Delta III Limited
Robert Lorne Hopfner		Series B Preferred Stock	Conversion of derivative security	-100%			-2,104,740	0	07 Nov 2025	By Pivotal bioVenture Partners Fund I, L.P.
Robert Lorne Hopfner		Series B Preferred Stock	Conversion of derivative security	-100%			-1,895,260	0	07 Nov 2025	By NFLS Delta III Limited
Robert Lorne Hopfner		Series A Preferred Stock	Conversion of derivative security	-100%			-7,230,283	0	07 Nov 2025	By Pivotal bioVenture Partners Fund I, L.P.
Robert Lorne Hopfner		Series A Preferred Stock	Conversion of derivative security	-100%			-2,582,243	0	07 Nov 2025	By NFLS Delta III Limited

* An asterisk sign (*) next to the price indicates that the price is likely invalid.